• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Animal & Veterinary

  • Print
  • Share
  • E-mail

NADA 041-061 Mecadox® 10 Type A Medicated Article - supplemental approval (October 5, 1998)

I. GENERAL INFORMATION:

NADA041-061
Sponsor:Pfizer, Inc.
812 Springdale Drive
Exton, Pennsylvania 19341-2803
Generic Name:Carbadox
Trade Name:Mecadox® 10 Type A Medicated Article
Marketing Status:Over the Counter (OTC)
Effect of Supplement:Provides for the establishment of a 42 day slaughter withdrawal period for carbadox in swine tissues and a limitation against use in pregnant swine or swine intended for breeding purposes.

II. INDICATIONS FOR USE

MecadoxÒ 10 is indicated for the control of dysentery and bacterial enteritis and for growth promotion in swine.

III. DOSAGE:

A.DOSAGE FORMMecadoxÒ 10 is indicated for the control of dysentery and bacterial enteritis and for growth promotion in swine.
B.ROUTE OF ADMINISTRATIONMecadoxÒ 10 is administered orally in finished feed.
C.RECOMMENDED DOSAGES:MecadoxÒ 10 is administered ad libitum in a final feed at a concentration of 10, 25, or 50 grams per ton.

IV. EFFECTIVENESS:

Studies demonstrating the efficacy of carbadox for the control of dysentery and bacterial enteritis and for growth promotion are documented in the Freedom of Information (FOI) Summary for the original approval for MecadoxÒ 10 under NADA 41-061.

V. ANIMAL SAFETY:

Studies demonstrating the safety of carbadox for use in swine is contained in the FOI Summary for the original approval for MecadoxÒ 10 under NADA 41-061.

VI. HUMAN SAFETY:

  1. Toxicity Studies: As documented in the Freedom of Information (FOI) Summary for NADA 41-061 dated January 30, 1998.
  2. Safe Concentrations of Total Residues: As documented in the FOI Summary for NADA 41-061 dated January 30, 1998.
  3. Total Residue and Metabolism Studies: As documented in the FOI Summary for NADA 41-061 dated January 30, 1998.
  4. Determination of the tolerance for the marker residue: As documented in the FOI Summary dated January 30, 1998, FDA selected liver as the target tissue and quinoxaline-2-carboxylic acid (QCA) as the marker residue. FDA determined that when QCA (marker residue) is at or below 30 ppb in the liver (target tissue) no residue of carcinogenic concern is detectable in each of the edible tissues by any method.
  5. Determination of the Withdrawal Time: Study Number 2522A-60-97-077

    1. Purpose: A tissue residue study was conducted to determine the depletion profile of quinoxaline-2-carboxylic acid (QCA) residue in uncooked porcine liver and muscle tissue following oral administration (via the feed) of carbadox (Mecadoxâ 10) for 28 days at 55 ppm (50 grams per ton) to growing swine.
    2. Investigators: This study was conducted in two phases.

      Phase one (live phase):

      Martha Ferris, D.V.M., M.S.
      Colorado Animal Research Enterprises, Inc.
      Fort Collins, CO 80524

       

      Phase two (analytical phase):

      Dr. Joe Boison
      Government of Canada
      Canadian Food Inspection Agency
      Centre for Veterinary Drug Residues
      Saskatoon, SK

    3. Animals: Thirty-four crossbred pigs (17 gilts and 17 barrows)
    4. Dosage form: Feed containing 55 ppm carbadox.
    5. Pertinent parameters measured: Muscle and liver were collected from each animal for QCA residue analysis. All of the tissue samples were analyzed in triplicate. For the purpose of establishing a withdrawal period only the liver residues were used.
    6. Results: See Table 1.

      Table 1.

      Arithmetic means (± SD) for quinoxaline-2-carboxylic acid
      (in ppb) in uncooked liver and muscle tissue of growing swine fed carbadox at 55 ppm for 28 days

       QCA Concentration (ppb)
      Treatment NumberDays Carbadox WithdrawnNo. of AnimalsLiverMuscle
      T214551.93 + 15.14<LOQ*
      T321529.09 + 8.20<LOQ
      T42857.72 + 4.72<LOQ
      T535511.23 + 1.86<LOQ
      T642311.16 + 2.13<LOQ
      T749110.90 + 2.35<LOQ
      *LOQ liver, muscle = 5 ppb
      LOD liver, muscle = 2 ppb
    7. Withdrawal period determination: A tolerance of 30 ppb was previously established for QCA (the marker residue) in swine liver (the target tissue). The withdrawal period was based on a statistical analysis of the depletion data, using an upper tolerance limit containing 99 percent of the population with a 95 percent confidence limit. Using the uncorrected residue data for liver from Days 14 to 49, a withdrawal period of 39.34 days was calculated. Based on this data, a 42-day withdrawal period was assigned for the use of MecadoxÒ 10 in swine.
  6. Regulatory method
    Residues of quinoxaline-2-carboxylic acid are determined using a gas chromatographic assay with electron capture detection. The method has a limit of quantification of 5 ppb. The method is on display in the Dockets Management Branch (HFA-305), Room 1061, 5630 Fishers Lane, Rockville, Maryland 20852.

VII. AGENCY CONCLUSIONS:

A tolerance of 30 ppb was previously established for QCA (the marker residue) in swine liver (the target tissue). With this supplemental NADA, a pre-slaughter withdrawal period of 42 days was assigned for the use of MecadoxÒ 10 (carbadox) Type A Medicated Article in swine feed. The withdrawal period was based on a statistical analysis of the depletion data, using an upper tolerance limit containing 99 percent of the population with a 95 percent confidence limit. The Limitations section in 21 CFR 558.115 will be amended to reflect the 42-day withdrawal period.

In accordance with 21 CFR 514.106(b)(2)(x), this is a Category II supplement. The approval of this change required a reevaluation of the slaughter withdrawal period according to current food safety guidance. Accordingly, this approval did not require a reevaluation of target animal safety or effectiveness data in the parent application.

The agency has determined under 21 CFR 25.33(a)(1) that this action is of a type that does not individually or cumulatively have a significant impact on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

Mecadox® 10 is not currently under any unexpired U.S. patents.

VIII. LABELING (Attached)

  1. Facsimile Bag Label - Mecadox ® 10 Type A Medicated Article
  2. Specimen (Bluebird) Type B Feed Medicated Feed
  3. Specimen (Bluebird) Type C Feed Medicated Feed

Copies of applicable labels may be obtained by writing to the:

Food and Drug Administration
Freedom of Information Staff (HFI-35)
5600 Fishers Lane
Rockville, MD 20857

Or requests may be sent via fax to: (301) 443-1726. If there are problems sending a fax, call (301) 443-2414.